Literature DB >> 20447549

Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.

Yukie Yoshii1, Takako Furukawa, Yasushi Kiyono, Ryo Watanabe, Atsuo Waki, Tetsuya Mori, Hiroshi Yoshii, Myungmi Oh, Tatsuya Asai, Hidehiko Okazawa, Michael J Welch, Yasuhisa Fujibayashi.   

Abstract

INTRODUCTION: (64)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a potential imaging agent of hypoxic tumor for use with PET. Recent literature demonstrated that cancer cells expressing CD133, which is a frequently used marker for so-called cancer stem cells or cancer stem cell-like cells (collectively referred to here as CSCs), contribute to tumor's therapeutic resistance and metastasis ability. Culturing under hypoxia is also reported to enlarge the proportion of CD133(+) cells, which would indicate survival advantage of CD133(+) cells under hypoxia. Here, we investigated the relationships between (64)Cu-ATSM accumulation and existence of CD133(+) cells using mouse colon carcinoma (colon-26) tumor.
METHODS: Intratumor distribution of (64)Cu-ATSM and (18)F-fluorodeoxyglucose ((18)FDG) was compared with immunohistochemical staining for CD133 with a colon-26 model. In vitro characterization of CD133(+) colon-26 cells was also performed.
RESULTS: In colon-26 tumors, (64)Cu-ATSM localized preferentially in regions with a high density of CD133(+) cells. The percentage of CD133(+) cells was 11-fold higher in (64)Cu-ATSM high-uptake regions compared with (18)FDG high- (but (64)Cu-ATSM low-) uptake regions. CD133(+) colon-26 cells showed characteristics previously linked with CSCs in other cancer cell lines, such as high colony-forming ability, high tumor-initiating ability and enrichment under hypoxic cultivation. The proportion of CD133(+) cells was enlarged by culturing under glucose starvation as well as hypoxia, and (64)Cu-ATSM uptake was increased under such conditions.
CONCLUSIONS: Our findings showed that, in colon-26 tumors, (64)Cu-ATSM accumulates in rich regions of CD133(+) cells with characteristics of CSCs. Therefore (64)Cu-ATSM could be a potential imaging agent for rich regions of CD133(+) cells, associated with CSCs, within tumors. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447549     DOI: 10.1016/j.nucmedbio.2009.12.011

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  Towards new horizons in brain PET.

Authors:  Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

Review 2.  Biological imaging in clinical oncology: radiation therapy based on functional imaging.

Authors:  Yo-Liang Lai; Chun-Yi Wu; K S Clifford Chao
Journal:  Int J Clin Oncol       Date:  2016-07-06       Impact factor: 3.402

Review 3.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

4.  [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation.

Authors:  Fang Xie; Weijun Wei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10       Impact factor: 10.057

Review 5.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

7.  Noninvasive identification of viable cell populations in docetaxel-treated breast tumors using ferritin-based magnetic resonance imaging.

Authors:  YoonSeok Choi; Hoe Suk Kim; Kyoung-Won Cho; Kyung-Min Lee; Yoon Jung Yi; Sung-Jong Eun; Hyun Jin Kim; Jisu Woo; Seung Hong Choi; Taeg-Keun Whangbo; ChulSoo Choi; Dong-Young Noh; Woo Kyung Moon
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

8.  Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission.

Authors:  Dayton D McMillan; Junko Maeda; Justin J Bell; Matthew D Genet; Garrett Phoonswadi; Kelly A Mann; Susan L Kraft; Hisashi Kitamura; Akira Fujimori; Yukie Yoshii; Takako Furukawa; Yasuhisa Fujibayashi; Takamitsu A Kato
Journal:  J Radiat Res       Date:  2015-08-06       Impact factor: 2.724

9.  Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection.

Authors:  Yukie Yoshii; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Takako Furukawa; Yukie Morokoshi; Chizuru Sogawa; Ming-Rong Zhang; Hidekatsu Wakizaka; Hiroshi Yoshii; Yasuhisa Fujibayashi; Tsuneo Saga
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

10.  Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET.

Authors:  Tetsuya Tsujikawa; Satoko Asahi; Myungmi Oh; Yoshitaka Sato; Norihiko Narita; Akira Makino; Tetsuya Mori; Yasushi Kiyono; Tatsuro Tsuchida; Hirohiko Kimura; Shigeharu Fujieda; Hidehiko Okazawa
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.